Posterior reversible encephalopathy syndrome with essential thrombocythemia A case report

被引:3
作者
Zhang, Yunqiao [1 ]
Lu, Zixiang [2 ]
Li, Yanping [2 ]
Wu, Jie [1 ]
Liu, Ting [3 ]
Xie, Xian [4 ]
He, Xiaolin [5 ]
Zeng, Yong [1 ]
机构
[1] Kunming Med Univ, Affiliated Hosp 6, Yuxi, Yunnan, Peoples R China
[2] Honghe Prefecture Second Peoples Hosp, Honghe, Peoples R China
[3] Xinjiang Med Univ, Affiliated Hosp 4, Urumqi, Xinjiang, Peoples R China
[4] Zhaotong Mental Hlth Ctr, Zhaotong, Peoples R China
[5] Yunnan Mental Hlth Ctr, Kunming, Yunnan, Peoples R China
关键词
essential thrombocythemia; posterior reversible encephalopathy syndrome; neurological disease; PLASMINOGEN-ACTIVATOR INHIBITOR; ENDOTHELIAL-CELLS; PLATELETS; THROMBOSIS; TYPE-1;
D O I
10.1097/MD.0000000000016759
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Rationale: Posterior reversible encephalopathy syndrome (PRES) is a rare neurological disease of the posterior subcortical white matter that manifests as headache, seizures, visual impairment, disturbance of consciousness, and changes in mental state. While PRES is associated with specific imaging findings involving the posterior circulation area of the brain. In the present study, we report the first case of PRES associated with essential thrombocythemia (ET). Patient concerns: A 49-year-old man suddenly experienced headache, followed by the gradual appearance of consciousness disorders and mental behavior abnormalities. Neurological tests showed that the patient had a Glasgow Coma Scale score of 12, normal muscle strength and tension of the limbs, and was negative for meningeal irritation. Diagnosis: Magnetic resonance imaging of the brain showed extensive vasogenic edema in the deep white matter of the right cerebellum and the left occipital and temporal lobes and a diagnosis of PRES was considered. Routine blood test showed that his platelet count was markedly increased, and the JAK2 V617F mutation analysis with allele-specific real-time polymerase chain reaction was positive. The bone marrow biopsy indicated an increasing number of megakaryocytes. These findings indicated ET. Interventions: PRES was treated with a dehydrating agent and supportive and symptomatic treatments. Aspirin tablets were prescribed to address the patient's ET. Outcome: After treatment, the abnormal findings on head imaging were completely reversed. His neurological symptoms were completely relieved. Lessons: PRES may be correlated with ET; specifically, ET may trigger PRES and be a risk factor for the acute onset of neurological deficits.
引用
收藏
页数:5
相关论文
共 25 条
[1]   Essential thrombocythemia in young individuals:: frequency and risk factors for vascular events and evolution to myelofibrosis in 126 patients [J].
Alvarez-Larran, A. ;
Cervantes, F. ;
Bellosillo, B. ;
Giralt, M. ;
Julia, A. ;
Hernandez-Boluda, J. C. ;
Bosch, A. ;
Hernandez-Nieto, L. ;
Clapes, V. ;
Burgaleta, C. ;
Salvador, C. ;
Arellano-Rodrigo, E. ;
Colomer, D. ;
Besses, C. .
LEUKEMIA, 2007, 21 (06) :1218-1223
[2]  
Arellano-Rodrigo E, 2006, HAEMATOL-HEMATOL J, V91, P169
[3]   Platelet turnover, coagulation factors, and soluble markers of platelet and endothelial activation in essential thrombocythemia: Relationship with thrombosis occurrence and JAK2 V617F allele burden [J].
Arellano-Rodrigo, Eduardo ;
Alvarez-Larran, Alberto ;
Reverter, Juan-Carlos ;
Colorner, Dolors ;
Villarnor, Neus ;
Bellosillo, Beatriz ;
Cervantes, Francisco .
AMERICAN JOURNAL OF HEMATOLOGY, 2009, 84 (02) :102-108
[4]   Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet [J].
Barbui, Tiziano ;
Barosi, Giovanni ;
Birgegard, Gunnar ;
Cervantes, Francisco ;
Finazzi, Guido ;
Griesshammer, Martin ;
Harrison, Claire ;
Hasselbalch, Hans Carl ;
Hehlmann, Rudiger ;
Hoffman, Ronald ;
Kiladjian, Jean-Jacques ;
Kroeger, Nicolaus ;
Mesa, Ruben ;
McMullin, Mary F. ;
Pardanani, Animesh ;
Passamonti, Francesco ;
Vannucchi, Alessandro M. ;
Reiter, Andreas ;
Silver, Richard T. ;
Verstovsek, Srdan ;
Tefferi, Ayalew .
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (06) :761-770
[5]   Thrombotic disease in the myeloproliferative neoplasms [J].
Falanga, Anna ;
Marchetti, Marina .
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2012, :571-581
[6]   RELATIONSHIP OF THROMBOHEMORRHAGIC COMPLICATIONS TO ENDOTHELIAL-CELL FUNCTION IN PATIENTS WITH CHRONIC MYELOPROLIFERATIVE DISORDERS [J].
FRIEDENBERG, WR ;
ROBERTS, RC ;
DAVID, DE .
AMERICAN JOURNAL OF HEMATOLOGY, 1992, 40 (04) :283-289
[7]  
Fugate JE, 2015, LANCET NEUROL, V14, P874, DOI [10.1016/S1474-4422(15)00195-7, 10.1016/S1474-4422(15)00111-8]
[8]   POTENTIAL ATTENUATION OF FIBRINOLYSIS BY GROWTH-FACTORS RELEASED FROM PLATELETS AND THEIR PHARMACOLOGIC IMPLICATIONS [J].
FUJII, S ;
LUCORE, CL ;
HOPKINS, WE ;
BILLADELLO, JJ ;
SOBEL, BE .
AMERICAN JOURNAL OF CARDIOLOGY, 1989, 63 (20) :1505-1511
[9]   MECHANISMS CONTRIBUTING TO INCREASED SYNTHESIS OF PLASMINOGEN-ACTIVATOR INHIBITOR TYPE-1 IN ENDOTHELIAL-CELLS BY CONSTITUENTS OF PLATELETS AND THEIR IMPLICATIONS FOR THROMBOLYSIS [J].
FUJII, S ;
HOPKINS, WE ;
SOBEL, BE .
CIRCULATION, 1991, 83 (02) :645-651
[10]   Posterior reversible encephalopathy syndrome-Insight into pathogenesis, clinical variants and treatment approaches [J].
Granata, Guido ;
Greco, Antonio ;
Iannella, Giannicola ;
Granata, Massimo ;
Manno, Alessandra ;
Savastano, Ersilia ;
Magliulo, Giuseppe .
AUTOIMMUNITY REVIEWS, 2015, 14 (09) :830-836